#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16680	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2093	791.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1408	1408	C	1002	C,A	911,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30022	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3614	828.8	0	.	n	.	0	T695C	SNP	695	695	T	1032	1032	C	919	C,T	831,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30022	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3614	828.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1674	1674	A	984	A	911	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30022	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3614	828.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2308	2308	C	975	C,T,G	884,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30022	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3614	828.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2382	2382	A	989	A	911	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30022	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3614	828.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2934	2934	C	1007	C	912	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	528	6	blaTEM	861	365	99.73	blaTEM.l6.c30.ctg.1	365	1.6	0	.	p	.	0	N152T	NONSYN	454	456	AAC	262	264	ACC	1;1;1	A;C;C	1;0;0	.	Betalactam resistance
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2134	folP	852	852	100.0	folP.l15.c4.ctg.1	1503	141.3	1	SNP	p	R228S	1	.	.	682	684	AGC	992	994	AGC	228;227;223	A;G;C	215;217;207	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5404	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3252	165.4	1	SNP	p	S91F	0	.	.	271	273	TCC	533	535	TCC	188;186;187	T;C;C	167;164;166	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5404	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3252	165.4	1	SNP	p	D95N	0	.	.	283	285	GAC	545	547	GAC	181;177;177	G;A;C	160;158;159	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5404	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3252	165.4	1	SNP	p	D95G	0	.	.	283	285	GAC	545	547	GAC	181;177;177	G;A;C	160;158;159	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1632	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1289	126.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	451	453	ACC	195;195;194	A,G;C;C	168,1;175;176	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1632	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1289	126.0	0	.	p	.	0	R44H	NONSYN	130	132	CGC	466	468	CAC	182;181;181	C;A;C	171;168;172	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1632	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1289	126.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	649	651	CAC	228;229;229	C;A;C	207;206;208	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1632	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1289	126.0	1	SNP	p	G45D	0	.	.	133	135	GGC	469	471	GGC	183;183;182	G;G;C	171;171;172	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	896	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1082	82.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5826	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2775	208.9	1	SNP	p	D86N	0	.	.	256	258	GAC	446	448	GAC	234;231;232	G;A;C	211;206;210	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5826	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2775	208.9	1	SNP	p	S87I	0	.	.	259	261	AGT	449	451	AGT	237;237;236	A,C;G;T	212,1;211;211	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5826	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2775	208.9	1	SNP	p	S87W	0	.	.	259	261	AGT	449	451	AGT	237;237;236	A,C;G;T	212,1;211;211	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5826	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2775	208.9	1	SNP	p	S87R	0	.	.	259	261	AGT	449	451	AGT	237;237;236	A,C;G;T	212,1;211;211	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5826	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2775	208.9	1	SNP	p	S88P	0	.	.	262	264	TCC	452	454	TCC	235;237;239	T;C;C	208;211;215	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4638	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2646	174.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1559	1561	GGC	223;221;220	G;G;C	204;203;202	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1184	1186	GCA	217;222;226	G,A;C;A	192,1;197;204	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1187	1189	ATC	228;227;228	A;T;C	207;206;207	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1199	1201	GTG	232;232;235	G;T;G	214;215;215	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1199	1201	GTG	232;232;235	G;T;G	214;215;215	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1703	1705	ACC	243;245;245	A;C;C	214;219;220	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1757	1759	GCG	215;213;218	G;C,G;G	185;163,1;179	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1757	1759	GCG	215;213;218	G;C,G;G	185;163,1;179	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1880	1882	GGC	219;214;209	G;G;C	196;189;191	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1889	1891	GGC	203;203;203	G;G;C	182;181;180	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4336	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2347	184.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1907	1909	CTG	195;196;195	C,G;T;GCCC,GCCCC	141,4;140;137,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6064	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	2911	207.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1545	1547	CTG	224;226;224	C;T;G,A	200;204;199,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2458	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1880	130.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	545	545	C	172	C	157	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	275	277	GGA	229;224;225	G;G;A	212;209;208	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	F135L	NONSYN	403	405	TTT	536	538	CTT	233;232;232	C,A;T;T	207,1;214;214	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	560	562	GGA	220;221;221	G;G;A	202;203;201	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	D171G	NONSYN	511	513	GAT	644	646	GGT	216;214;215	G;G;T	198;196;195	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	G189S	NONSYN	565	567	GGC	698	700	AGC	218;218;215	A;G;C	204;202;200	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	.	INDELS	619	621	AAA	753	758	TCGAAT	212;205;203;201;197;193	T;C;G;A;A;T	199;193;190;190;187;184	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	.	INDELS	622	624	AAA	760	766	CTACGAT	191;196;196;197;196;193;194	C;T;A;C;G,A;A;T	182;187;187;188;185,1;187;188	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	.	MULTIPLE	628	630	GAA	771	774	AAAC	194;193;196;197	A;A,G;A;C	190;185,1;189;188	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	N212Y	NONSYN	634	636	AAT	779	781	TAT	195;194;195	T;A;T	188;187;186	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	I214M	NONSYN	640	642	ATC	785	787	ATG	199;201;202	A;T;G	183;184;181	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	L218F	NONSYN	652	654	CTT	797	799	TTT	226;227;229	T;T;T	202;202;203	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	A238V	NONSYN	712	714	GCC	857	859	GTT	246;246;245	G;T;T	227;230;229	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	T252A	NONSYN	754	756	ACA	899	901	GCA	249;247;248	G;C,T;A	234;232,1;233	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	W253T	NONSYN	757	759	TGG	902	904	ACG	244;248;245	A;C;G	229;232;229	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	S254R	NONSYN	760	762	AGT	905	907	AGG	245;244;244	A;G;G,T	228;229;227,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	A255V	NONSYN	763	765	GCT	908	910	GTT	241;241;242	G;T;T	224;219;223	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	L275V	NONSYN	823	825	TTA	968	970	GTA	255;251;251	G;T;A	229;223;227	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	S288T	NONSYN	862	864	TCT	1007	1009	ACT	256;259;258	A;C;T	224;231;228	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	H290D	NONSYN	868	870	CAT	1013	1015	GAT	261;264;264	G;A;T	235;238;236	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	S291D	NONSYN	871	873	AGT	1016	1018	GAT	264;263;262	G;A;T,A	239;239;236,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	D293N	NONSYN	877	879	GAC	1022	1024	AAC	273;274;275	A;A;C	245;242;243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	Y294H	NONSYN	880	882	TAC	1025	1027	CAC	280;278;282	C;A;C	247;245;251	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	0	.	p	.	0	E329D	NONSYN	985	987	GAA	1130	1132	GAC	248;250;250	G;A;C	224;226;229	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	1	SNP	p	G120K	0	.	.	358	360	GGT	491	493	GGT	232;226;225	G;G;T,G	218;212;207,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	1	SNP	p	A121N	0	.	.	361	363	GCC	494	496	GCC	221;221;218	G;C;C	207;207;203	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2854	porB1b	1035	1035	96.08	porB1b.l15.c17.ctg.1	1313	212.3	1	SNP	p	A121D	0	.	.	361	363	GCC	494	496	GCC	221;221;218	G;C;C	207;207;203	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11660	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4676	248.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1869	1871	AAT	284;286;286	A;A;T	259;262;262	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1158	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1114	103.6	1	SNP	p	V57M	1	.	.	169	171	ATG	583	585	ATG	255;256;259	A;T;G	233;233;238	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
